KLN-1010

Phase 1Small molecule

KKelonia Therapeutics, Inc.

KLN-1010 is one of 3 small molecule programs targeting Multiple Myeloma in Relapse. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple Myeloma in RelapseRecruiting

Multiple Myeloma in RelapsePhase 1

Recruiting

Competition

Competitive Landscape

3 competitors in Multiple Myeloma in Relapse

#DrugCompanyPhaseTrials

Xpovio

KKaryopharm Therapeutics Inc

Phase 2

1 2

Rapamycin

MMaastricht Radiation Oncology

Phase 1

1 3

KLN-1010

KKelonia Therapeutics, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2042

Phase 1Recruiting

Multiple Myeloma in Relapse

NCT07075185

Clinical

Trials by Indication[1]

Multiple Myeloma in Relapse1 trial

A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma

Recruiting·KKelonia Therapeutics, Inc.·Phase 1·NCT07075185·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for KLN-1010. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KLN-1010 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KLN-1010. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kelonia Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: KKelonia Therapeutics, Inc.

KLN-1010

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2042

Trials by Indication[1]

Multiple Myeloma in Relapse1 trial

References

Drug Info

Quick Facts

Related News